Company Overview and News

PPG Industries: Comex Acquisition Should Begin to Pay Off

2016-01-06 fool
PPG has been the Rodney Dangerfield among paint and coatings stocks, but the measures it has taken since 2014 should begin to earn it some respect in 2016.

My Top Chemicals Stocks For 2016

2015-12-31 seekingalpha
In this series of articles, I will be reviewing individual industry sectors and selecting my favorite stock picks for 2016.For this article, I will be reviewing the Chemicals industry sector, taking a

8 Companies Scheduled To Announce Annual Dividend Increases In December And The 13 That Announced In November

2015-12-01 seekingalpha
Last month, I predicted that thirteen members of the S&P 1500 with 20 year histories of dividend increases would announce their annual increased in November. I missed one dividend increase - CDK Globa

Johnson Controls Is Cheap - Cramer's Lightning Round (11/20/15)

2015-11-29 seekingalpha
Sirius XM Holdings has a good business model.Lam Research is a better pick than Applied Materials.PPG Industries and Masco are the picks from the paint group.

RPM International, Inc. Earnings Q1, 2016

2015-11-29 capitalcube
RPM International, Inc. reports financial results for the quarter ended August 31, 2015.We analyze the earnings along side the following peers of RPM International, Inc. – Valspar Corporation and H.B. Fuller Company (VAL-US and FUL-US) that have also reported for this period.HighlightsSummary numbers: Revenues of USD 1,242.53 million, Net Earnings of USD 99.82 million, and …

Platform Specialty Products Corp. – Value Analysis (NYSE:PAH) : November 24, 2015

2015-11-29 capitalcube
Click here to see latest analysisCapitalcube gives Platform Specialty Products Corp. a score of 21.Our analysis is based on comparing Platform Specialty Products Corp. with the following peers – Bemis Company, Inc., PPG Industries, Inc., E. I. du Pont de Nemours and Company, Dow Chemical Company, Exxon Mobil Corporation, Chevron Corporation, Valspar Corporation and Sherwin-Williams …

Low Expense, Low Fuss, Income Growth

2015-11-29 seekingalpha
Income growth investing is ideal for ultra-passive investment programs.Focus on proven companies with timeless businesses.Once a year, review, reinvest, and then ignore.

The Valspar's (VAL) CEO Gary Hendrickson on Q4 2015 Results - Earnings Call Transcript

2015-11-27 seekingalpha
The Valspar Corp. (NYSE:VAL) Q4 2015 Earnings Conference Call November 24, 2015 11:00 AM ET Executives Bill Seymour - VP, Investor Relations Gary Hendrickson – Chairman and Chief Executive Officer Jim

What Do Hedge Funds Think of The Valspar Corporation (VAL)?

2015-11-26 insidermonkey
Is The Valspar Corporation (NYSE:VAL) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because...

6 Dividend Stocks Working Hard During The Holidays

2015-11-26 seekingalpha
Many of us in the U.S. will get a few days off this week in observance of the Thanksgiving holiday. Even though I am not working, my dividend growth stocks are hard at work providing me an additional

J.P. Morgan now favoring PPG over Valspar in coatings

2015-11-25 seekingalpha
PPG Industries (NYSE:PPG) rose 0.9% today, and Valspar (NYSE:VAL) dropped 1.4%, as J.P. Morgan says it now prefers PPG in the chemical coatings space. Morgan's Jeffrey Zekauskas downgraded Valspar to

Valspar (VAL) Beats on Q4 Earnings; Currency Hurts Sales

Valspar (VAL) surpassed earnings expectations but missed on revenues in the fourth quarter of fiscal 2015.

Valspar (VAL) Beats on Q4 Earnings; Currency Hurts Sales

2015-11-25 zacks
Valspar (VAL) surpassed earnings expectations but missed on revenues in the fourth quarter of fiscal 2015.

Top Analyst Upgrades and Downgrades: AmEx, Carnival, eBay, HP, IAMGOLD, Pfizer, Tech Data and Many More

2015-11-25 247wallst
Stocks were indicated surprisingly higher after international markets recovered more than might have been expected. The trend that has been static for 4 years now is that investors want to buy stocks on weakness and pullbacks. 24/7 Wall St. reviews dozens of analyst reports each day of the week in order to find new investing and trading ideas for its readers. Some analyst reports cover stocks to buy, while other calls cover stocks to sell or stock to avoid.

Edited Transcript of VAL earnings conference call or presentation 24-Nov-15 4:00pm GMT

Q4 2015 Valspar Corp Earnings Call

Related Articles

ACIA: Acacia Communications Analysis and Research Report

4m - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...